Company news

Xenon Pharmaceuticals Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference

October 1, 2024

Xenon Showcases Azetukalner Data at 15th European Epilepsy Congress

September 8, 2024

Xenon Expands Leadership Team with Matthew D. Ronsheim, Ph.D. as Chief Operating Officer

August 11, 2024

Xenon to Report Q2 2024 Financial Results on August 8, 2024

July 31, 2024

Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

June 4, 2024

Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting

May 27, 2024

Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 8, 2024

Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2024

May 7, 2024

Xenon Pharmaceuticals to Present at the 2024 RBC Capital Markets Global Healthcare Conference

May 6, 2024

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Corporate Update

May 1, 2024

Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting

April 15, 2024

Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

April 9, 2024

Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference

April 3, 2024

Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days

March 11, 2024

Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024

March 4, 2024

Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

February 28, 2024

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update

February 21, 2024

Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2024

January 7, 2024

Xenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 2, 2024

Xenon Pharmaceuticals Announces Closing of $345.0 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

December 3, 2023

Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023)

December 1, 2023

Xenon Pharmaceuticals Announces Proposed Public Offering

November 28, 2023

Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering

November 28, 2023

Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept X-NOVA Clinical Trial of XEN1101 in Major Depressive Disorder (MDD)

November 26, 2023

Xenon Pharmaceuticals Provides Update on Partnered Program with Neurocrine Biosciences

November 8, 2023

Xenon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

November 7, 2023

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Corporate Update

October 31, 2023

Xenon Pharmaceuticals Announces Publication of Results from XEN1101 Phase 2b “X-TOLE” Clinical Trial in Peer-Reviewed Journal Article in JAMA Neurology

October 8, 2023

Xenon Pharmaceuticals to Present at Jefferies Inaugural Biotech CNS/Neuro Summit

October 5, 2023

Xenon Pharmaceuticals to Present at TD Cowen’s 3rd Annual Novel Mechanisms in Neuropsychiatry Summit

September 13, 2023

Xenon Pharmaceuticals Announces Upcoming Investor Webinar with Leading Key Opinion Leaders to Discuss XEN1101 and Major Depressive Disorder

September 11, 2023

Xenon Pharmaceuticals Showcases XEN1101 Epilepsy Program at 35th International Epilepsy Congress

September 3, 2023

Xenon Pharmaceuticals to Present at the Wells Fargo 2023 Healthcare Conference

August 30, 2023

Xenon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

August 8, 2023

Xenon Pharmaceuticals Expands Leadership on its Board of Directors with Appointments of Gillian M. Cannon and Justin Gover

August 7, 2023

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Second Quarter 2023 Financial Results and Provide Corporate Update

August 1, 2023

Xenon Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

June 5, 2023

Xenon Pharmaceuticals to Present at the 2023 Jefferies Healthcare Conference

May 30, 2023

Xenon Pharmaceuticals to Present at the 2023 RBC Capital Markets Global Healthcare Conference

May 10, 2023

Xenon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 8, 2023

Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2023

May 2, 2023

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Corporate Update

May 1, 2023

Xenon Pharmaceuticals Showcases Its XEN1101 Epilepsy Program at the 2023 American Academy of Neurology (AAN) Annual Meeting

April 23, 2023

Xenon Pharmaceuticals to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

April 20, 2023

Xenon Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference

April 17, 2023

Xenon Pharmaceuticals to Present at the Stifel 2023 CNS Days

March 21, 2023

Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

February 28, 2023

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update

February 21, 2023

Xenon Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference

February 7, 2023

Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2023

January 8, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 22 calls. Every call is listed under its year.

Decks

The 5 newest of 6 decks. Every deck is listed under its year.